Login / Signup

Life after ibrutinib? A new unmet need in CLL.

Javier A Pinilla-IbarzJulio C Chavez
Published in: Blood (2015)
In this issue of Blood, Jain et al reported on the poor outcomes of patients with chronic lymphocytic leukemia (CLL) after the discontinuation of ibrutinib.
Keyphrases
  • chronic lymphocytic leukemia
  • metabolic syndrome
  • adipose tissue